Oncolytics Biotech (ONCY) EBT Margin (2009 - 2020)
Oncolytics Biotech (ONCY) posted quarterly EBT Margin of 16.37% for Q3 2020, up 506.0% year-over-year from 2.7% in Q4 2019, and down 12.65% quarter-over-quarter from 14.53% in Q2 2020.
Oncolytics Biotech (ONCY) EBT Margin (2009 - 2020) Analysis & Trends
Oncolytics Biotech (ONCY) has reported EBT Margin for 7 consecutive years, with 16.37% the latest figure, recorded in Q3 2020.
- In Q3 2020, EBT Margin rose 506.0% year-over-year to 16.37%; the TTM figure through Sep 2020 stood at 16.24% (down 1624.0% YoY), while the FY2018 annual figure was 0.0%, changed N/A from the prior year.
- EBT Margin declined to 16.37% in Q3 2020 per ONCY's latest filing, from 14.53% in the prior quarter.
- Across five years, EBT Margin topped out at 18650.71% in Q3 2018 and bottomed at 34.76% in Q2 2019.
- Historically, EBT Margin has averaged 2105.03% across 5 years, with a median of 0.0% in 2019.
- Annual changes were most pronounced in 2019 — EBT Margin plunged 1867214 bps — and 2020, when it surged 2023 bps.
- Oncolytics Biotech's EBT Margin stood at 381.71% in 2016, then tumbled by 100 bps to 0.0% in 2017, then slumped by 96 bps to 0.0% in 2018, then plunged by 68209708 bps to 21.43% in 2019, then grew by 24 bps to 16.37% in 2020.
- Business Quant data shows ONCY's EBT Margin at 16.37% in Q3 2020, 14.53% in Q2 2020, and 21.43% in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.14 Bn | 132.29 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 87.02 Bn | 79.03 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 65.30 Bn | 60.12 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 60.84 Bn | 55.70 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 42.15 Bn | 37.06 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.49 Bn | 28.18 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.78 Bn | 10.38 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.14 Bn | 26.31 Bn | - | 12.09% |
| 10 | Oncolytics Biotech | 97.56 Mn | 97.56 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | -16.37% |
| Jun 30, 2020 | -14.53% |
| Sep 30, 2019 | -21.43% |
| Jun 30, 2019 | -34.76% |
| Mar 31, 2019 | 0.00% |
| Dec 31, 2018 | 0.00% |
| Sep 30, 2018 | 18,650.71% |
| Jun 30, 2017 | 0.00% |
| Jun 30, 2016 | 381.71% |
| Jun 30, 2010 | 1,403.86% |
| Dec 31, 2009 | -5,228.79% |
| Sep 30, 2009 | 26.31% |
| Jun 30, 2009 | 33.98% |
| Mar 31, 2009 | 40.38% |